Lucid Diagnostics Inc. announced on September 26, 2025 that John R. Palumbo has been appointed to its Board of Directors, effective September 22, 2025.
Palumbo brings 40 years of healthcare leadership, having guided early‑stage ventures, growth companies, and Fortune 100 firms. He served as Executive Chairman of ValueHealth, led a 2018 recapitalization and a 2022 strategic investment, and held senior roles at AmerisourceBergen, Allscripts, and I‑trax, where he built national primary‑care and population‑health platforms.
His experience in scaling companies, navigating IPOs, and transforming complex organizations positions him to provide strategic guidance as Lucid approaches key commercial milestones, including Medicare coverage, direct contracting expansion, and the rollout of its EsoGuard diagnostic platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.